Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific's Ultraflex

This article was originally published in The Gray Sheet

Executive Summary

Esophageal stent system for the "palliative treatment of advanced esophageal cancer" is approved by FDA. Constructed of Elastalloy, "a highly flexible titanium-based mesh," Ultraflex is inserted in the esophagus "to exert a constant, gentle force that helps keep the passage open" despite obstructive tumors. The firm is promoting the device as superior to rubber or plastic stents, which are "poorly tolerated in half of all patients"



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts